Literature DB >> 12784030

Progression of dementia associated with lacunar infarctions.

Judith Aharon-Peretz1, Ella Daskovski, Tatiana Mashiach, Dorita Kliot, Rachel Tomer.   

Abstract

BACKGROUND: Lacunar stroke (L) is the most common stroke subtype associated with vascular dementia (VaD-L).
OBJECTIVE: To evaluate the cognitive and behavioral course in patients with probable VaD-L.
METHODS: We longitudinally measured rates of change on MMSE, digit span, logical memory, Controlled Oral Word Association, CERAD battery and neuropsychiatric inventory (NPI) in 77 patients (age at entry 69 +/- 8.1 years) with probable VaD-L for 25.75 +/- 11 months.
RESULTS: The mean number of follow-up visits was 2.6 +/- 0.67 (range 2-4). Time interval between any two consecutive visits was at least 5 months (range 5-41). MMSE deteriorated by 1.44+/- 1.8 points annually and NPI increased by 6.01 +/- 13.7 points annually (p < 0.0001). The rates of cognitive and behavioral decline were predominantly influenced by the cognitive state at entry into the study and the occurrence of new vascular episodes during follow-up [(-0.95 +/- 1.7) MMSE and (+2.02 +/- 14.1) NPI points annually without vascular episodes vs. (-2.09 +/- 1.6) and (+11.3 +/- 11.4) points following vascular episodes (p < 0.0001)]. Impaired cognition was associated with impaired behavior (p < 0.001). VaD-L patients without additional vascular episodes at follow-up have a progressively deteriorating course as well (p < 0.0001).
CONCLUSION: VaD-L is characterized by cognitive and behavioral decline. The rate of decline is determined mainly by the severity of the cognitive and behavioral impairment at baseline and by the occurrence of new vascular episodes. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12784030     DOI: 10.1159/000070678

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  7 in total

1.  Age, gender, and education are associated with cognitive performance in an older Israeli sample with type 2 diabetes.

Authors:  Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; James Schmeidler; Jeremy M Silverman; Mary Sano; Keren Koifmann; Rachel Preiss; Hadas Hoffman; Anthony Heymann; Michal Schnaider Beeri
Journal:  Int J Geriatr Psychiatry       Date:  2013-08-08       Impact factor: 3.485

2.  Vascular cognitive impairment.

Authors:  Alladi Suvarna
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

3.  Association between gait features assessed by artificial intelligent system and cognitive function decline in patients with silent cerebrovascular disease: study protocol of a multicenter prospective cohort study (ACCURATE-2).

Authors:  Yan-Min Tang; Bei-Ni Fei; Xin Li; Jin Zhao; Wei Zhang; Guo-You Qin; Min Hu; Jing Ding; Xin Wang
Journal:  BMC Neurol       Date:  2022-06-30       Impact factor: 2.903

4.  Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.

Authors:  Gerda G Fillenbaum; Gerald van Belle; John C Morris; Richard C Mohs; Suzanne S Mirra; Patricia C Davis; Pierre N Tariot; Jeremy M Silverman; Christopher M Clark; Kathleen A Welsh-Bohmer; Albert Heyman
Journal:  Alzheimers Dement       Date:  2008-03       Impact factor: 21.566

5.  Vascular cognitive impairment: Current concepts and Indian perspective.

Authors:  Suvarna Alladi; Subhash Kaul; Shailaja Mekala
Journal:  Ann Indian Acad Neurol       Date:  2010-12       Impact factor: 1.383

6.  Characteristics of dynamic cerebral autoregulation in cerebral small vessel disease: Diffuse and sustained.

Authors:  Zhen-Ni Guo; Yingqi Xing; Shuang Wang; Hongyin Ma; Jia Liu; Yi Yang
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

7.  Study protocol on Alzheimer's disease and related disorders: focus on clinical and imaging predictive markers in co-existing lesions.

Authors:  Nawele Boublay; Denis Fédérico; Alain Pesce; Marc Verny; Frédéric Blanc; Marc Paccalin; Thomas Desmidt; Pierre Grosmaître; Olivier Moreaud; Solveig Relland; Estelle Bravant; Romain Bouet; Pierre Krolak-Salmon
Journal:  BMC Geriatr       Date:  2018-11-14       Impact factor: 3.921

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.